Anpario plc (FRA:KI9A)

Market Cap	130.81M +40.5%
Revenue (ttm)	54.08M +23.5%
Net Income	7.74M +64.2%
EPS	0.43 +55.4%
Shares Out	n/a
PE Ratio	16.90
Forward PE	15.45
Dividend	0.15 (2.38%)
Ex-Dividend Date	Jul 9, 2026

Volume	n/a
Open	6.10
Previous Close	6.10
Day's Range	6.10 - 6.20
52-Week Range	4.12 - 7.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2026

About Anpario

Anpario plc, together with its subsidiaries, manufactures and distributes animal feed additives for animal health, nutrition, and biosecurity in the Americas, Asia, Europe, the Middle East, and Africa. The company offers animal gut health products, such as phytogenic and acid based eubiotics, and omega fatty acids under the AmpLIPhy, Orego-Stim, Optomega, pHorce, Salkil, and Genex brands; and feed products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Feedzyme, Salgard, Oxigard, Mol...

• Industry: Food and Kindred Products
• Founded: 1996
• Employees: 162
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KI9A

Financial Performance

In 2025, Anpario's revenue was 47.18 million, an increase of 23.51% compared to the previous year's 38.20 million. Earnings were 6.75 million, an increase of 64.20%.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 18, 2026

Data Sources Report a data error